Clinical Hematology International

Volume 2, Issue 3, September 2020, Pages 109 - 116

Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors

Authors
Natasha A. Jain1, , ORCID, Marcus Y. Chen2, , Sujata Shanbhag2, Prathima Anandi1, Xin Tian3, Sawa Ito1, Priyanka A. Pophali1, Kimberly Doucette1, Robert Q. Le1, Upneet Chawla1, Eleftheria Koklanaris1, Richard W. Childs1, A. John Barrett1, Minoo Battiwalla1, 4, *
1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
2Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
3Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
4Sarah Cannon Blood Cancer Network, Nashville, TN, USA

Contributed equally

*Corresponding author. Postal address: Tristar Centennial Blood and Marrow Transplant, 2300 Patterson Street, 5th Floor, Nashville, TN 37203, USA. Tel.: +1 301 742 7782; Fax: +1 615 342 7462; Email: minoo.battiwalla@hcahealthcare.com
Corresponding Author
Minoo Battiwalla
Received 22 February 2020, Accepted 6 May 2020, Available Online 12 June 2020.
DOI
10.2991/chi.d.200508.001How to use a DOI?
Keywords
Coronary CT angiogram; cardiovascular risk; survivorship; BMT; late effects
Abstract

Long-term allogeneic hematopoietic cell transplant (allo-HCT) survivors suffer an elevated risk of coronary heart disease (CHD). We conducted a prospective, nonrandomized, cross-sectional study to screen asymptomatic survivors at a single allo-HCT center using cardiac computed tomography (CT) involving coronary CT angiography (CCTA) and the coronary artery calcium (CAC) score. Seventy-nine subjects with a median age of 39 years at allo-HCT and a median follow-up interval of 8 years were evaluated for CHD by Framingham Risk Score (FRS) and cardiac CT. CHD was detected in 33 of 79 (42%) subjects; 91% of lesions were nonobstructive, 19.5% of were noncalcified and 30% had associated valvular calcification. Overall, CAC was significantly superior to FRS in detecting early CHD in allo-HCT survivors [∆C = 0.25; P < 0.0001]. While both FRS and CAC were highly, >95% specific, FRS had a sensitivity, positive and negative predictive values of only 28% (95% CI, 14%–47%), 90% (95% CI, 55%–100%) and 60% (95% CI, 47%–73%), respectively. In contrast, the sensitivity, positive and negative predictive values of CAC were 78% (95% CI, 60%–91%), 96% (95% CI, 80%–100%) and 83% (95% CI, 69%–93%), respectively. Significantly, cardiac CT detected CHD in 23 of the 68 (34%) survivors deemed to have a low Framingham risk. Radiation exposure during cardiac CT was negligible, and there were no adverse events. In conclusion, CAC score with or without CCTA is a safe, feasible and sensitive screening technique for CHD. The FRS greatly underestimates CHD in allo-HCT survivors.

Copyright
© 2020 National Institutes of Health. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Clinical Hematology International
Volume-Issue
2 - 3
Pages
109 - 116
Publication Date
2020/06/12
ISSN (Online)
2590-0048
DOI
10.2991/chi.d.200508.001How to use a DOI?
Copyright
© 2020 National Institutes of Health. Publishing services by Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Natasha A. Jain
AU  - Marcus Y. Chen
AU  - Sujata Shanbhag
AU  - Prathima Anandi
AU  - Xin Tian
AU  - Sawa Ito
AU  - Priyanka A. Pophali
AU  - Kimberly Doucette
AU  - Robert Q. Le
AU  - Upneet Chawla
AU  - Eleftheria Koklanaris
AU  - Richard W. Childs
AU  - A. John Barrett
AU  - Minoo Battiwalla
PY  - 2020
DA  - 2020/06/12
TI  - Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors
JO  - Clinical Hematology International
SP  - 109
EP  - 116
VL  - 2
IS  - 3
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.200508.001
DO  - 10.2991/chi.d.200508.001
ID  - Jain2020
ER  -